$APLMW News

Last published 2d ago

2d agoAPLM APLMWApollomics Reports First-Half 2026 Financial ResultsGlobeNewswirePhase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. FOSTER CITY, Calif., Nov. 09, 2026
3mo agoAPLM APLMWApollomics Announces $10 Million Private Placement TransactionGlobeNewswireFOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug
4mo agoAPLM APLMWApollomics Regains Full Compliance with Nasdaq Listing RequirementsGlobeNewswireFOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug
4mo agoAPLM APLMWApollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in AsiaGlobeNewswireFOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug
6mo agoAPLM APLMWApollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business ProgressGlobeNewswirePhase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.To date, more than 600 patients and 170
7mo agoAPLM APLMWApollomics Inc. Announces $2.0 Million Bridge FinancingGlobeNewswireFOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the
10mo agoAPLM APLMWApollomics Reports First Half 2025 Financial ResultsGlobeNewswireFOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
11mo agoAPLM APLMWApollomics Announces Settlement of Cayman LitigationGlobeNewswireFOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (NASDAQ:APLM) announced today entering into a settlement agreement (the "Settlement Agreement" or the "Agreement")
11mo agoAPLM APLMWApollomics Announces Changes to its Board of Directors and Composition of CommitteesGlobeNewswireFOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California-based late-stage clinical biopharmaceutical company, today announced the following
1y agoAPLM APLMWApollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing CancellationGlobeNewswireFOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug
1y agoAPLM APLMW NDAQNasdaq Resumes Trading in Apollomics Inc.GlobeNewswireNEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:APLM) and warrants (NASDAQ:APLMW) at 9:00
1y agoAPLM APLMWApollomics, Inc. Company Operational Continuity UpdateGlobeNewswireFOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage
1y agoAPLM APLMW NDAQNasdaq Halts Apollomics Inc., Ltd.GlobeNewswireNEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional
1y agoAPLM APLMWApollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business ProgressGlobeNewswireStrategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for
1y agoAPLM APLMWApollomics and LaunXP Announce Development and Commercialization Agreement for VebreltinibGlobeNewswireLaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung
1y agoAPLM APLMWApollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid LeukemiaGlobeNewswireFOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
1y agoAPLM APLMWApollomics Regains Compliance with Nasdaq's Minimum Bid Price RequirementGlobeNewswireFOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today
1y agoAPLM APLMWApollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share SplitGlobeNewswireFOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
2y agoAPLM APLMWApollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024GlobeNewswireFOSTER CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
2y agoAPLM APLMWApollomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireFOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
2y agoAPLM APLMWApollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressGlobeNewswireContinued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9 million in cash and cash
2y agoAPLM APLMWApollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA TrialGlobeNewswireFOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
2y agoAPLM APLMWApollomics to Present at the Canaccord Genuity 44th Annual Growth ConferenceGlobeNewswireFOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
2y agoAPLM APLMWApollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireFOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
2y agoAPLM APLMWApollomics Announces Updated Strategic Focus and Leadership Team ChangesGlobeNewswireFOSTER CITY, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
2y agoAPLM APLMWApollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireFOSTER CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
2y agoAPLM APLMWApollomics Announces Presentation at the 2024 BIO International ConventionGlobeNewswireFOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (NASDAQ:APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address
2y agoAPLM APLMWApollomics Announces Private Placement Financing and Addition to Board of DirectorsGlobeNewswireFOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and
2y agoAPLM APLMWApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneGlobeNewswireApollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval based on
2y agoAPLM APLMWApollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireFOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented
2y agoAPLM APLMWApollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireFOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today
2y agoAPLM APLMWApollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsGlobeNewswireContinued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in
2y agoAPLM APLMWApollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024GlobeNewswireFOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today
2y agoAPLM APLMWApollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerGlobeNewswireFOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today
2y agoAPLM APLMWApollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewswireFOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today
2y agoAPLM APLMWApollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireFOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today
2y agoAPLM APLMWApollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology ConferenceGlobeNewswireFOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today
2y agoAPLM APLMW GLYCApollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewswireFOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat
2y agoAPLM APLMWApollomics to Present at the 2024 Biotech ShowcaseGlobeNewswireFOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today
2y agoAPLM APLMWApollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationGlobeNewswireTreatment of NSCLC patients with MetExon14 skipping mutation with and without co-occurring MET amplification, reflecting "real-world"1 setting FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc.
2y agoAPLM APLMWApollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceGlobeNewswireFOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address
2y agoAPLM APLMWApollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)GlobeNewswireFOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address
2y agoAPLM APLMWApollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerGlobeNewswireApollomics' partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China Compelling clinical data serving as basis of
3y agoAPLM APLMWApollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationGlobeNewswireFOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and
3y agoAPLM APLMWApollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionGlobeNewswireFOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with
3y agoAPLM APLMWApollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%GlobeNewswireFOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the
3y agoAPLM APLMWApollomics Announces Presentations of Vebreltinib Data at ESMO 2023GlobeNewswireFOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address
3y agoAPLM APLMWApollomics Reports First Half 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and
3y agoAPLM APLMWApollomics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireFOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address
3y agoAPLM APLMWApollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller SymposiumGlobeNewswireFOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and